We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

10 Top Penny Stocks To Watch This Week With Potential Biotech Catalysts

3 23 17

Here we are at the start of a new week and a new list of penny stocks to watch. This has become a frequent installment on our weekly outlook on markets with a focus on one industry. Biotechnology is one of the areas of the stock market with constant volatility. It doesn’t matter if we’re talking about cheap stocks on Robinhood under $5 or large-cap stocks trading above $100.

Since this industry has oversight bodies like the Food And Drug Administration, certain things must be upheld based on rules that’ve been in place for decades. Part of this set of rules has to do with things like phase trials. Whether it’s pre-clinical, clinical, or commercial launch, steps are needed and proof required to move forward with any drug candidate or medical device.

There are also plenty of forms and applications that get filed along the way, allowing for FDA and other global biotech oversight groups to give guidance or even completely shut down a company’s pipeline development. Then you’ve got other things specific to companies unrelated to any FDA event.

Read more: 4 Hot OTC Penny Stocks To Watch For October 2021

These are things like industry conferences and investor engagements. The bottom line is, unlike other industries, biotech has plenty of moving parts that can act as catalysts in the stock market. Today we’ll look at 10 penny stocks to watch this week with potential biotech catalysts. Will they be on the buy- or avoid-side of your watch list?

The first name on this list of penny stocks kicks things off tomorrow. Soligenix specializes in treatments for several indications. Its SGX301 (HyBryte) platform addresses cutaneous T-cell lymphoma and is awaiting regulatory approval after completing a Phase 3 study. Solivenix has also developed its SGX302 (Hypericin) in treating psoriasis.

Soligenix is also part of the popular COVID-19 vaccine grouping of stocks. The company is developing CiVax™, which is currently under observation in non-human primates. The vaccine candidate has shown protective effects against the SARS-CoV-2 variant and was recently featured in the article, “Protein Vaccine Induces a Durable, More Broadly Neutralizing Antibody Response in Macaques than Natural Infection with SARS-CoV-2 P.1.”

This week is all about the HyBryte platform. An abstract was selected and accepted for display and presentation at the National Organization for Rare Disorders Rare Diseases and Orphan Products Breakthrough Summit. The company will present the positive Phase 3 results with HyBryte™ in the context of the broader cutaneous T-cell lymphoma treatment landscape. This Summit begins on October 18th.

This week will be a very active week of conference presentations, as you’ll see in the next section. Transcode Therapeutics will have a presence at one of these conferences early during the week.

Read more: 5 Top Penny Stocks Analysts Say To Buy With 119%-430% Price Targets

The company went public earlier this summer and has since fought back to regain its IPO levels unsuccessfully. Transcode is developing RNA oncology treatments targeting multiple indications. Its lead therapeutic candidate, TTX-MC138, is under development for addressing metastatic cancer. According to the company, TTX-MC138 has the potential to produce regression without recurrence in a wide range of cancers such as breast, pancreatic, ovarian, and colon cancer, as well as........

© Entrepreneur

Get it on Google Play